Liquidia (NASDAQ:LQDA) Insider Sells $84,739.35 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sanjeev Khindri sold 1,185 shares of the business’s stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $71.51, for a total value of $84,739.35. Following the sale, the insider directly owned 65,947 shares of the company’s stock, valued at $4,715,869.97. This represents a 1.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sanjeev Khindri also recently made the following trade(s):

• On Monday, June 8th, Sanjeev Khindri sold 4,134 shares of Liquidia stock. The stock was sold at an average price of $65.46, for a total value of $270,611.64.

Liquidia Stock Down 3.2%

NASDAQ LQDA opened at $75.27 on Friday. The stock’s 50-day moving average price is $67.74 and its 200-day moving average price is $48.10. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 52 week low of $14.04 and a 52 week high of $82.96. The company has a market capitalization of $6.69 billion, a P/E ratio of 537.68 and a beta of 0.55.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. The company had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm’s revenue for the quarter was up 4187.1% on a year-over-year basis. On average, equities research analysts predict that Liquidia Corporation will post 3.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

LQDA has been the topic of several analyst reports. HC Wainwright lifted their price target on shares of Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a report on Friday, June 5th. Oppenheimer set a $75.00 price objective on shares of Liquidia in a research note on Friday, June 5th. Needham & Company LLC raised their price objective on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Wall Street Zen cut shares of Liquidia from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 27th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $68.00 price target on shares of Liquidia in a research note on Thursday, June 4th. Three equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $68.88.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Liquidia during the fourth quarter valued at about $25,000. NewEdge Advisors LLC purchased a new stake in shares of Liquidia in the second quarter worth about $25,000. FNY Investment Advisers LLC purchased a new stake in shares of Liquidia in the third quarter worth about $34,000. Covestor Ltd boosted its stake in Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after buying an additional 359 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Liquidia by 281.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after buying an additional 4,927 shares during the last quarter. Institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).